Scott Cannizzaro is excited to announce that the company he co-founded, Evolus (EOLS, NASDAQ), was granted FDA approval for it’s first product Jeuveau™. Scott commented, “I had the privilege of working with an exceptional team to bring this product to market - it’s an exciting time and the company is in a great position to go after this exciting market.” Jeuveau™ is the first aesthetic-only neurotoxin approved in the U.S. Launch is planned for Spring 2019.
Contact Dr. Scott at:
[email protected]